Name | Relationship | Address | Signature | Signature date | CIK |
---|---|---|---|---|---|
BOCHNOWSKI JAMES J | Director | C/O JAGUAR HEALTH, INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO | /s/ James J. Bochnowski | 2025-06-26 | 0001255743 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | JAGX | Convertible Promissory Note | Disposed to Issuer | -$4.05B | -27K | -100% | $150,000.00 | 0 | Jun 24, 2025 | Common Stock | 27K | $5.56 | See footnote | F1, F3 |
transaction | JAGX | Convertible Promissory Note | Award | $4.26B | +28.4K | $150,000.00 | 28.4K | Jun 24, 2025 | Common Stock | 28.4K | $5.56 | See footnote | F1, F3 | |
transaction | JAGX | Warrant to Purchase Common Stock | Award | +54.8K | 27K | Jun 24, 2025 | Common Stock | 54.8K | $2.70 | See footnote | F2, F3 |
Id | Content |
---|---|
F1 | The reporting person disposed of a 6% convertible promissory note maturing on 6/30/2025 (the "Original Note") that was originally issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 in exchange for a new 6% convertible promissory note that matures on 1/30/2026 (the "New Note") in an issuer exchange offer. The New Note is convertible, at the reporting person's option, in part or in full, into an aggregate of 28,388 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share. |
F2 | As an inducement to enter into the issuer exchange offer, the reporting person received a warrant (the "Warrant") to purchase up to 54,786 shares of Common Stock with an exercise price of $2.70 per share. The Warrant is exercisable immediately upon receipt of stockholder approval and will expire on the earlier of (i) 18 months from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event. |
F3 | Securities held directly by the Bochnowski Family Trust. Mr. Bochnowski, by virtue of his position as a co-trustee and beneficiary of such trust and his sharing of voting and investment control over the securities held by the trust with his spouse, may be deemed to beneficially own the securities held by the Bochnowski Family Trust for purposes of Section 16 |